Nasdaq:IMNM
Immunome Inc.
A clinical-stage biopharmaceutical firm engineering next-generation immunotherapies for autoimmune diseases via a proprietary R&D platform.
Key Metrics
Investment Thesis
Bull Case
Immunome offers high upside potential for investors seeking exposure to autoimmune disease treatments that could redefine standard of care if clinical trials succeed. The company's strong cash position relative to its burn rate allows it to pursue multiple pipeline candidates without immediate revenue pressure, and strategic licensing deals provide non-dilutive income streams.
Bear Case
Revenue declined from $14.0M in 2023 to $9.0M in the latest period while net losses widened dramatically, indicating unsustainable current business models without commercial product sales. With accumulated deficits exceeding $500M and no significant revenue diversification beyond R&D spend, the stock faces high volatility and dilution risks if future financing rounds are required.
About Immunome Inc.
Immunome Inc. is a biopharmaceutical company developing therapeutic candidates to treat immune-mediated inflammatory diseases such as rheumatoid arthritis and lupus. The company leverages its proprietary immunology platform to engineer novel biologics, primarily targeting the North American market through clinical-stage programs. Key revenue streams include product licensing agreements and potential commercialization of approved therapies once milestones are reached.
Analysis
Management Discussion
The company reported a net loss of $293.0M in 2024, a substantial increase in magnitude from the previous year, driven by elevated research and development expenditures totaling $129.5M. Operating cash flow was negative at $110.8M, though the balance sheet remains robust with $143.4M in cash and equivalents, while recent financing activities provided $240.5M to extend operational runway.
Industry Overview
The biopharmaceutical sector for autoimmune diseases is competitive but offers massive market opportunities with billions in potential addressable demand for novel immunotherapies. Companies like Immunome face intense pressure to demonstrate clinical efficacy and safety to secure regulatory approval and attract partner interest, often requiring substantial capital investment before reaching profitability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $14.0M | $9.0M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $14.0M | $9.0M |
| Operating Expenses | $36.9M | $123.5M | $314.8M |
| Operating Income | $-36.9M | $-109.5M | $-305.8M |
| R&D | $23.3M | $23.1M | $129.5M |
| G&A | $13.6M | $19.7M | $33.0M |
| Stock-Based Comp | $5.3M | $6.2M | $15.7M |
| D&A | $422.0K | $457.0K | $1.6M |
| Other OpEx | $0 | $80.8M | $152.3M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-36.9M | $-109.5M | $-305.8M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-36.9M | $-109.5M | $-305.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-36.9M | $-106.8M | $-293.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-36.9M | $-106.8M | $-293.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $22.6M | $144.7M | $221.3M |
| Cash & Equivalents | $20.3M | $98.7M | $143.4M |
| Prepaid Expenses | $2.3M | $6.6M | $4.0M |
| Other Current Assets | $0 | $39.5M | $74.0M |
| Long-Term Assets | $1.4M | $3.8M | $18.9M |
| PP&E (Net) | $681.0K | $2.1M | $10.1M |
| Operating Leases | $284.0K | $1.6M | $4.3M |
| Other LT Assets | $432.0K | $200.0K | $4.5M |
| Total Assets | $24.0M | $148.5M | $240.2M |
| Current Liabilities | $7.3M | $21.8M | $54.3M |
| Accounts Payable | $2.4M | $3.3M | $14.2M |
| Current Leases | — | — | $63.0K |
| Deferred Revenue | — | $10.5M | $6.9M |
| Other Current Liab | $4.9M | $8.0M | $33.1M |
| Long-Term Liabilities | $62.0K | $6.8M | $4.8M |
| LT Operating Leases | — | — | $4.8M |
| Other LT Liab | — | $1.3M | $0 |
| Total Liabilities | $7.4M | $28.7M | $59.1M |
| Shareholders' Equity | $16.7M | $119.9M | $181.2M |
| Paid-In Capital | $132.7M | $342.7M | $696.9M |
| Retained Earnings | $-116.0M | $-222.8M | $-515.8M |
| AOCI | — | $22.0K | $57.0K |
| Total L&E | $24.0M | $148.5M | $240.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-36.9M | $-106.8M | $-293.0M |
| Non-Cash Adjustments | $14.2M | $79.6M | $182.7M |
| Working Capital Changes | $-6.0M | $19.7M | $-488.0K |
| Cash from Operations | $-28.7M | $-7.6M | $-110.8M |
| Capital Expenditures | $248.0K | $831.0K | $7.2M |
| Cash from Investing | $-248.0K | $-30.5M | $-85.1M |
| Cash from Financing | $32.0K | $116.4M | $240.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-28.9M | $78.4M | $44.7M |
| Beginning Cash | $49.3M | $20.4M | $98.8M |
| Ending Cash | $20.4M | $98.8M | $143.5M |
Frequently Asked Questions
How does Immunome Inc. make money?
Therapeutic Development (licensing fees, milestone payments, and royalty revenues from external partners), Pre-Clinical Research (internal program development costs), and Commercialization (future sales of approved products once market entry occurs).
What are the main risks for IMNM?
Significant net losses and cash burn without current product revenue limiting financial runway, high regulatory and clinical trial failure risks inherent to biotech development, reliance on external funding sources due to negative operating cash flow, and potential dilution from share issuances to finance operations.
What is IMNM's competitive advantage?
Proprietary immunology platform enabling the design of highly specific biologics with reduced off-target effects, a streamlined R&D pipeline reducing time-to-market, and strategic partnerships that mitigate upfront commercial risk.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.